Lucid Diagnostics (LUCD) Stock Price, News & Analysis

Company Overview

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Key Stats

• Today's Range: $1.21 to $1.30
• 50-Day Range: $1.09 to $1.65
• 52-Week Range: $0.68 to $1.80
• Volume: 1.37 million shs
• Average Volume: 572,066 shs
• Market Capitalization: $139.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.55
• Consensus Rating: Buy

Lucid Diagnostics Stock Analysis - MarketRank™

Lucid Diagnostics scored higher than 60% of companies evaluated by MarketBeat, and ranked 392nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Lucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lucid Diagnostics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.84) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lucid Diagnostics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lucid Diagnostics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.41% of the float of Lucid Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Lucid Diagnostics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lucid Diagnostics has recently increased by 32.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lucid Diagnostics does not currently pay a dividend.

Dividend Growth

Lucid Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.41% of the float of Lucid Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Lucid Diagnostics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lucid Diagnostics has recently increased by 32.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.53

News Sentiment

Lucid Diagnostics has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for LUCD on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.80% of the stock of Lucid Diagnostics is held by insiders.

Percentage Held by Institutions

74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LUCD Stock Analysis - Frequently Asked Questions

How have LUCD shares performed this year?

Lucid Diagnostics' stock was trading at $0.8187 at the start of the year. Since then, LUCD shares have increased by 57.6% and is now trading at $1.29.
View the best growth stocks for 2025 here.

How were Lucid Diagnostics' earnings last quarter?

Lucid Diagnostics Inc. (NASDAQ:LUCD) announced its earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share (EPS) for the quarter. The company earned $1.04 million during the quarter.
Read the conference call transcript.

When did Lucid Diagnostics IPO?

Lucid Diagnostics (LUCD) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share.

Who are Lucid Diagnostics' major shareholders?

Top institutional shareholders of Lucid Diagnostics include Alyeska Investment Group L.P. (1.79%), Ghisallo Capital Management LLC (0.40%), XML Financial LLC (0.20%) and Goldman Sachs Group Inc. (0.08%).
View institutional ownership trends.

How do I buy shares of Lucid Diagnostics?

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lucid Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Netflix (NFLX), Clean Energy Fuels (CLNE) and Baidu (BIDU).

Company Calendar

• Last Earnings: 3/26/2024
• Today: 6/07/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LUCD
• CIK: 1799011
• Web: www.luciddx.com
• Phone: 212-949-4319
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.55
• High Stock Price Target: $7.75
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +175.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.67 million
• Net Margins: -1,069.87%
• Pretax Margin: -1,069.90%
• Return on Equity: N/A
• Return on Assets: -123.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.18
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: $4.17 million
• Price / Sales: 33.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.47) per share
• Price / Book: -2.74

Miscellaneous

• Outstanding Shares: 108,189,000
• Free Float: 54,120,000
• Market Cap: $139.56 million
• Optionable: No Data
• Beta: 1.31